4,4-bis(4-fluorophenyl)-2-butanone | 53135-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4-bis(4-fluorophenyl)-2-butanone
• 英文别名: 4,4-bis(4-fluorophenyl)butan-2-one
• CAS: 53135-12-9
• 化学式: C₁₆H₁₄F₂O
• 分子量: 260.283
• InChiKey: GYZTVFNFFUUBDM-UHFFFAOYSA-N

物化性质

• 沸点：
  331.8±32.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,4-bis(4-fluorophenyl)-2-butanone 在 盐酸 、 ammonium formate 作用下， 以 二氯甲烷 为溶剂， 反应 1.25h， 生成
  参考文献：
  名称：

  Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

  摘要：

  Analogues of the potent histamine H-2 agonist arpromidine, characterized by non-heterocyclic groups (phenyl, cyclo-hexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H-2 agonistic and H-1 antagonistic activity in the isolated guinea pig right atrium and ileum, respectively. In the diphenylpropylguanidine series an increase in H-2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 less-than-or-equal-to 7.75 vs pD2 = 7.15 for the unsubstituted parent compound). Compounds chlorinated at both phenyl rings were considerably less potent. Highest combined H-2 agonistic/H-1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium. The H-1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series. Thus, aromatic rings appear not to be required for high H-2 agonistic potency but are useful for combined H-2 agonistic/H-1 antagonistic activity.

  DOI：

  10.1016/0223-5234(92)90145-q
• 作为产物：
  描述：

  氯代双(4-氟苯基甲烷) 在 sodium hydroxide 、 sodium 作用下， 以 四氢呋喃 为溶剂， 反应 11.0h， 生成 4,4-bis(4-fluorophenyl)-2-butanone
  参考文献：
  名称：

  Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

  摘要：

  Analogues of the potent histamine H-2 agonist arpromidine, characterized by non-heterocyclic groups (phenyl, cyclo-hexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H-2 agonistic and H-1 antagonistic activity in the isolated guinea pig right atrium and ileum, respectively. In the diphenylpropylguanidine series an increase in H-2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 less-than-or-equal-to 7.75 vs pD2 = 7.15 for the unsubstituted parent compound). Compounds chlorinated at both phenyl rings were considerably less potent. Highest combined H-2 agonistic/H-1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium. The H-1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series. Thus, aromatic rings appear not to be required for high H-2 agonistic potency but are useful for combined H-2 agonistic/H-1 antagonistic activity.

  DOI：

  10.1016/0223-5234(92)90145-q

文献信息

• Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β2-adrenoceptor agonists
  作者：Ce Yi、Gang Xing、Siqi Wang、Xiaoran Li、Yichuang Liu、Jinyan Li、Bin Lin、Anthony Yiu-Ho Woo、Yuyang Zhang、Li Pan、Maosheng Cheng

  DOI：10.1016/j.bmc.2019.115178

  日期：2020.1

  β2-adrenoceptor agonists with an 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one moiety is presented. The stimulatory effects of the compounds on human β2-adrenoceptor and β1-adrenoceptor were characterized by a cell-based assay. Their smooth muscle relaxant activities were tested on isolated guinea pig trachea. Most of the compounds were found to be potent and selective agonists of the β2-adrenoceptor

  提出了一系列具有2-（1-氨基-1-羟乙基）-6-羟基-1,4-苯并恶嗪-3（4H）-一个部分的β2-肾上腺素受体激动剂。通过基于细胞的测定来表征化合物对人β2-肾上腺素能受体和β1-肾上腺素能受体的刺激作用。在分离的豚鼠气管上测试了它们的平滑肌松弛活性。发现大多数化合物是β2-肾上腺素能受体的有效和选择性激动剂。其中一种化合物（R）-18c具有很强的β2-肾上腺素受体激动作用，EC50值为24 pM。它产生了与奥洛他特罗相同的充分而有效的气道平滑肌松弛作用。在体外豚鼠气管支气管扩张模型中，它的起效时间为3.5分钟，作用时间超过12小时。
• Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β2-adrenoceptor agonists
  作者：Gang Xing、Li Pan、Ce Yi、Xiaoran Li、Xinyue Ge、Ying Zhao、Yichuang Liu、Jinyan Li、Anthony Woo、Bin Lin、Yuyang Zhang、Maosheng Cheng

  DOI：10.1016/j.bmc.2018.10.043

  日期：2019.6

  A series of novel β2-adrenoceptor agonists with a 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one moiety was designed, synthesized and evaluated for biological activity in human embryonic kidney 293 cells and isolated guinea pig trachea. Compounds 9g and (R)-18c exhibited the most excellent β2-adrenoceptor agonistic effects and high β2/β1-selectivity with EC50 values of 36 pM for 9g and 21 pM

  设计，合成了一系列具有5-（2-氨基-1-羟乙基）-8-羟基喹啉-2（1H）-一个部分的新型β2-肾上腺素受体激动剂，并评估了其在人胚胎肾293细胞中的生物学活性。豚鼠气管。化合物9g和（R）-18c表现出最出色的β2-肾上腺素受体激动作用和高β2/β1-选择性，9g的EC50值为36 pM，（R）-18c的EC50值为21 pM。他们在体外豚鼠气管支气管扩张模型中产生了有效的气道平滑肌松弛作用，起效快，作用时间长。这些结果支持将这两种化合物进一步发展为候选药物。
• Photocatalytic Hydroacylation of Alkenes by Directly Using Acyl Oximes
  作者：Lan Zheng、Peng-Ju Xia、Qing-Lan Zhao、Yu-En Qian、Wen-Nian Jiang、Hao-Yue Xiang、Hua Yang

  DOI：10.1021/acs.joc.0c01818

  日期：2020.9.18

  are directly used as the acyl radical precursors in the hydroacylation reactions for the first time. In this work, acyl radicals can be effectively generated viaβ-scission of a phosphoranyl radical under photocatalytic conditions. As a result, the hydroacylation of alkenes triggered by the resulting acyl radicals leads to facile syntheses of a range of valuable ketones.

  首次将酰基肟直接用作加氢酰化反应中的酰基自由基前体。在这项工作中，通过在光催化条件下磷酰基的β-断裂可以有效地产生酰基。结果，由所得的酰基自由基引发的烯烃的加氢酰化导致容易地合成一系列有价值的酮。
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2014043019A1

  公开（公告）日：2014-03-20

  The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公式I所涵盖的化合物包括HIV蛋白酶抑制剂和其他可在体内代谢为HIV蛋白酶抑制剂的化合物。这些化合物及其药学上可接受的盐对于预防或治疗HIV感染以及预防、治疗或延迟艾滋病的发作非常有用。这些化合物及其盐可以作为药物组合物的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• AMIDE COMPOUNDS AND THE USE THEREOF
  申请人：Matsumura Akira

  公开号：US20110190300A1

  公开（公告）日：2011-08-04

  The invention relates to amide compounds of Formula I: (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl, etc.; R 1 and R 2 are each independently hydrogen, halogen, cyano, optionally substituted lower alky, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl etc. R 3 and R 4 are hydrogen, each optionally substituted lower alkyl, cycloalkyl, aryl or heterocyclyl etc.; X is ═O, optionally substituted lower alkyl, halogen, cyano, nitro etc., n is 0-5, m is 1 or 2 and p is 0-2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及公式I的酰胺化合物：（I）及其药学上可接受的盐，前药和溶剂化物，其中：Y为CO或SOm；Z为每个可选取代的较低烷基，较低烯基，环烷基，芳基，杂环烷基等；R1和R2分别独立地为氢，卤素，氰基，可选取代的较低烷基，可选取代的环烷基，可选取代的芳基或可选取代的杂环烷基等。R3和R4为氢，每个可选取代的较低烷基，环烷基，芳基或杂环烷基等；X为═O，可选取代的较低烷基，卤素，氰基，硝基等，n为0-5，m为1或2，p为0-2。本发明还涉及使用公式I的化合物治疗、预防或改善对钙通道阻滞剂有反应的疾病，特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。